There are 2789 resources available
207P - Outcomes of patients with triple-negative breast cancer following neoadjuvant chemotherapy with anthracycline and taxane-based regimens plus carboplatin
Presenter: Bryan Vaca Cartagena
Session: ePoster Display
208P - ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC
Presenter: Peter Schmid
Session: ePoster Display
209P - Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
Presenter: Samuel Klempner
Session: ePoster Display
305P - Real-world health-related quality of life (HRQoL) among HER2-negative (HER2-) advanced breast cancer (ABC) patients in EU3 and US
Presenter: Katie Lewis
Session: ePoster Display
8P - The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel
Presenter: Yoichi Ozawa
Session: ePoster Display
9P - Click Activated Protodrugs Against Cancer (CAPAC) platform enhances the safety, pharmacokinetics, and antitumor efficacy of cancer therapies in vivo
Presenter: Sangeetha Srinivasan
Session: ePoster Display
10P - DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Presenter: Hirokazu Suzuki
Session: ePoster Display
11P - Profiling adaptive responses of renal cell cancer to cabozantinib in order to develop rational drug combinations
Presenter: Diego Tosi
Session: ePoster Display
12P - The design and development of novel pentaranes: Paving the way to EMT inhibition in triple-negative breast cancer cells
Presenter: Alexander Scherbakov
Session: ePoster Display